Potential roles of histone deacetylases in diabetic wound healing

Table 1 Histone deacetylase inhibitors approved by the Food and Drug Administration for clinical use[163-172]

Inhibitor	Target	Application	Ref.
Vorinostat (SAHA)	Broad-spectrum, mainly targets HDAC1, HDAC2, HDAC3, and HDAC6	Relapsed or refractory cutaneous T-cell lymphoma, multiple myeloma	Kim et al[163]; Olsen et al[164]; Sborov et al[165]
Romidepsin (FK228)	Selectively targets HDAC1 and HDAC2	Relapsed or refractory cutaneous T cell lymphoma and peripheral T cell lymphoma, multiple myeloma	Piekarz et al[166]; Harrison et al[167]
Belinostat (PXD101)	Broad-spectrum, targets HDAC1-9	Relapsed or refractory peripheral T cell lymphoma	O'Connor et al[168]
Panobinostat (LBH589)	Broad-spectrum, targets HDAC1-11	Relapsed or relapsed and refractory multiple myeloma	San-Miguel et al[169]
Givinostat (DUVYZAT™)	Pan-HDAC inhibitor	Duchenne muscular dystrophy	Lamb[170]
Chidamide	Class I HDAC inhibitor	Relapsed or refractory extranodal natural killer T-cell lymphoma, relapsed or refractory peripheral T cell lymphoma	Shi et al[171]; Gao et al[172]

HDAC: Histone deacetylase.